Your session is about to expire
← Back to Search
Informational Intervention for Cancer Communication
N/A
Waitlist Available
Led By Joseph A Arthur
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
First outpatient consultation visit with a palliative care specialist
Diagnosis of advanced cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
Study Summary
This trial is testing whether information materials can help communication between patients with cancer and their caregivers and physicians.
Who is the study for?
This trial is for English-speaking cancer patients with advanced disease visiting a palliative care specialist for the first time, along with their caregivers who are involved in their care. Participants must be able to understand and communicate effectively without cognitive impairments. Physicians seeing these patients on the study day can also join.Check my eligibility
What is being tested?
The study compares two ways of sharing information: 'Question Prompt Sheet' (QPS), designed to encourage active patient participation and questions, versus standard general information sheets given during consultations between physicians, patients, and caregivers.See study design
What are the potential side effects?
Since this trial involves informational interventions rather than medical treatments or drugs, there are no direct physical side effects expected from participating in this study.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have seen a palliative care specialist for the first time as an outpatient.
Select...
My cancer is in an advanced stage.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Patients' perception of helpfulness (0-10 scale) in communicating with their physicians after the first consultation visit
Secondary outcome measures
Average speaking time of patient or physician during the consultation visit affected by QPS
Caregivers' perception of helpfulness in communicating with their physicians
Change in patient anxiety state scores before and after consultation between the QPS and the GIS
+4 moreSide effects data
From 2020 Phase 3 trial • 177 Patients • NCT0181707513%
Rash maculo-papular
10%
Skin and subcutaneous tissue disorders - Other, specify
1%
Mucositis oral
1%
Sepsis
1%
Skin ulceration
1%
Urticaria
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm I (CHG Cleansing Wipe)
Arm II (Control)
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Group I (QPS)Experimental Treatment2 Interventions
Participants receive QPS and answer questions from physician. At follow up visit, participants receive both QPS and GIS.
Group II: Group II (GIS)Active Control2 Interventions
Participants receive GIS and answer questions from physician. At follow up visit, participants receive both QPS and GIS.
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
2,966 Previous Clinical Trials
1,804,574 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,932,946 Total Patients Enrolled
Joseph A ArthurPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
84 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have seen a palliative care specialist for the first time as an outpatient.I do not want to participate in the study.My cancer is in an advanced stage.I brought someone with me to the clinic.I have a caregiver actively involved in my health care.
Research Study Groups:
This trial has the following groups:- Group 1: Group I (QPS)
- Group 2: Group II (GIS)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any available slots left in this experiment for participants?
"According to the clinicaltrials.gov listing, this study has ceased recruitment as of October 20th 2022 and is no longer searching for participants. Despite that, 2423 other trials are actively recruiting patients at present."
Answered by AI
Popular Categories
Share this study with friends
Copy Link
Messenger